Stock listing
Lang & Schwarz:A2N478 IXICO PLC Aktie
German listing (Lang & Schwarz) of IXICO PLC · home listing LSE:IXI
Follow IXICO PLC into a list and get an email when it puts out news.
Home listing price · LSE:IXI
13.00p GBX (pence) +0.25 (+2.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:IXI
- Day range
- 12.50p – 13.35p GBX (pence)Nov 20, 2026
- Volume
- 23,918 sharesNov 20, 2026
- Market cap
- £28.47M GBPAt the close on Nov 20, 2026 · price × 219.0M shares outstanding
- 52-week range
- 6.26p – 17.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £18,221 GBPMedian day 30,172 shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:IXI · Home | 13.00p GBX (pence) | +0.25 (+2.0%) | 23,918 | 13.00p | 13.35p | 12.50p | 12.75p | Close on Nov 20, 2026 |
| OTC:PHYOF | $0.07 USD | 0.00 (0.0%) | — | $0.07 | $0.07 | $0.07 | $0.07 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:IXI · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 13.00p | +0.25 | +2.0% | 13.00p | 13.35p | 12.50p | 23,918 | |
| 12.75p | 0.00 | 0.0% | 12.75p | 13.00p | 12.50p | 107,957 | |
| 12.75p | 0.00 | 0.0% | 12.75p | 13.30p | 12.57p | 148,370 | |
| 12.75p | 0.00 | 0.0% | 12.75p | 13.00p | 12.50p | 2,216 | |
| 12.75p | -0.25 | -1.9% | 13.00p | 13.13p | 12.50p | 152,188 | |
| 13.00p | 0.00 | 0.0% | 13.00p | 13.10p | 12.68p | 43,337 | |
| 13.00p | 0.00 | 0.0% | 13.00p | 13.17p | 12.50p | 97,883 | |
| 13.00p | 0.00 | 0.0% | 13.00p | 13.25p | 13.00p | 2,631 | |
| 13.00p | 0.00 | 0.0% | 13.00p | 13.25p | 12.50p | 44,655 | |
| 13.00p | -1.50 | -10.3% | 14.25p | 14.44p | 12.26p | 308,569 | |
| 14.50p | -1.00 | -6.5% | 15.50p | 16.00p | 14.25p | 334,713 | |
| 15.50p | 0.00 | 0.0% | 15.50p | 16.00p | 15.00p | 103,021 | |
| 15.50p | +1.50 | +10.7% | 15.75p | 17.00p | 15.00p | 751,620 | |
| 14.00p | +2.25 | +19.1% | 12.25p | 16.50p | 12.00p | 2,649,879 | |
| 11.75p | 0.00 | 0.0% | 11.75p | 12.00p | 11.55p | 92,889 | |
| 11.75p | 0.00 | 0.0% | 11.75p | 12.33p | 11.60p | 186,557 | |
| 11.75p | 0.00 | 0.0% | 11.75p | 12.50p | 11.50p | 326,352 | |
| 11.75p | +1.50 | +14.6% | 10.25p | 12.50p | 9.50p | 693,198 | |
| 10.25p | +0.25 | +2.5% | 10.00p | 11.00p | 9.50p | 18,738 | |
| 10.00p | +0.25 | +2.6% | 9.50p | 11.00p | 9.50p | 287,601 | |
| 9.75p | +1.25 | +14.7% | 9.25p | 10.00p | 8.50p | 780,801 | |
| 8.50p | 0.00 | 0.0% | 8.50p | 9.00p | 8.00p | 20,815 | |
| 8.50p | +0.75 | +9.7% | 8.25p | 10.00p | 8.00p | 1,336,670 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 8.50p | 7.00p | 3,307 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 8.50p | 7.00p | 58,391 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 8.50p | 7.00p | 172 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 8.25p | 7.55p | 5,999 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 8.50p | 7.55p | 42,414 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 8.50p | 7.455p | 17,645 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 8.199p | 7.455p | 8,415 | |
| 7.75p | -0.25 | -3.1% | 7.75p | 8.50p | 7.455p | 7,685 | |
| 8.00p | 0.00 | 0.0% | 8.00p | 8.50p | 7.65p | 137,816 | |
| 8.00p | 0.00 | 0.0% | 8.00p | 8.50p | 7.65p | 2,302 | |
| 8.00p | +0.50 | +6.7% | 7.50p | 8.50p | 7.00p | 165,115 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 10,788 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 7.68p | 7.50p | 1,000 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 7.50p | 7.50p | 0 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 7.80p | 7.255p | 166,218 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 15,383 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.50p | 12,529 | |
| 7.50p | +0.10 | +1.4% | 7.399p | 7.75p | 7.399p | 106,916 | |
| 7.40p | -0.10 | -1.3% | 7.25p | 7.50p | 7.075p | 235,066 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.11p | 95,108 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 7.50p | 7.15p | 143 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.15p | 10,914 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 332 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 7.50p | 7.15p | 59,282 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 17,227 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.15p | 1,981 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 299,096 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 10,741 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 30,987 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 7.575p | 7.50p | 1,716 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 7,403 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.166p | 12,823 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.33p | 57,826 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 7.75p | 7.50p | 20,000 | |
| 7.50p | -0.25 | -3.2% | 7.75p | 8.00p | 7.00p | 70,164 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 7.75p | 7.75p | 0 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 7.75p | 7.556p | 60,000 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 7.75p | 7.556p | 8,219 | |
| 7.75p | 0.00 | 0.0% | 7.75p | 7.75p | 7.75p | 0 | |
| 7.75p | +0.25 | +3.3% | 7.69p | 8.50p | 7.69p | 30,172 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.30p | 14,386 | |
| 7.50p | 0.00 | 0.0% | 7.50p | 8.00p | 7.00p | 1,669 |
Splits
1 split · LSE:IXI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-50 | Consolidation |
- Ticker
- Lang & Schwarz:A2N478
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
IXI Platform & Collaborations Update
Latest earnings call · May 19, 2026
IXICO (LSE:IXI) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Apr 1, 2026
Investor Day (April 2026)
Investor day · 20 slides
Latest news
IXI Platform & Collaborations Update
Nov 19, 2026
Closed 13.00p (+2.0%) on Nov 20, 2026
New Alzheimer's AI Tool
Nov 17, 2026
Closed 12.75p (0.0%) on Nov 17, 2026
£2.7m clinical phase 3 contract win
Nov 2, 2026
Closed 14.00p (+19.1%) on Nov 2, 2026
IXICO Presents New Huntington's Disease Research
Oct 29, 2026
Closed 11.75p (0.0%) on Oct 29, 2026
Alzheimer's contract wins
Oct 22, 2026
Closed 9.75p (+14.7%) on Oct 22, 2026
Trading Update
Oct 20, 2026
Closed 8.50p (+9.7%) on Oct 20, 2026
IXICO present PD research at radiology conference
Oct 1, 2026
Closed 7.50p (0.0%) on Oct 1, 2026
HD Industry Update
Jul 13, 2026
Closed 8.25p (-10.8%) on Jul 13, 2026
Exercise of Options
Jun 19, 2026
Closed 8.65p (0.0%) on Jun 19, 2026
Scientific advisors & partners update
Jun 8, 2026
Closed 8.65p (0.0%) on Jun 8, 2026
IXICO PLC on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 27 in the last 12 months · 343 in all · newest Nov 19, 2026 · oldest 1999
- Calls
- 14 calls with a replay · 14 with a transcript · latest May 19, 2026
- Decks
- 11 decks · latest Apr 1, 2026
Where IXICO PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:IXI · Home listing | LSE | United Kingdom | GBX |
| OTC:PHYOF | OTC | United States | USD |
| LS Exchange:A2N478 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2N478 · This page | Lang & Schwarz | Germany | EUR |
| Frankfurt:PYPB | Frankfurt | Germany | EUR |
| Stuttgart:PYPB | Stuttgart | Germany | EUR |
Valuation
EV/sales 4.2× against a median of 0.8×: 9th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Sep 30, 2025 · balance Mar 31, 2026 · price Nov 20, 2026
- Enterprise value
- £27.35M GBP
- P/E
- Loss
- EV/sales
- 4.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.7×
- Gross margin
- 44.5%
- Operating margin
- −38.7%
- Net margin
- −25.3%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| IXICO PLC · LSE:IXI | US$37.27M | US$35.81M | n/a | 4.2× | n/a | 2.7× | −25.3% | 0.1× | n/a |
| Osang Healthcare Co. Ltd. · KRX:036220 | US$42.35M | US$24.18M | n/a | 0.3× | n/a | 0.2× | −8.8% | 0.1× | n/a |
| ABL Diagnostics SA · EURONEXT:ABLD | US$41.28M | US$42.32M | 38.1× | 5.5× | 42.8× | 5.3× | 14.2% | 0.3× | n/a |
| hVIVO plc · LSE:HVO | US$41.01M | US$42.24M | n/a | 0.7× | 7.5× | 1.0× | −12.8% | 0.4× | n/a |
| Harvard Bioscience, Inc. · NASDAQ:HBIO | US$39.60M | US$71.90M | n/a | 0.8× | 28.4× | 7.8× | −13.2% | 7.3× | 1.34 |
| CytoGen, Inc. · KRX:217330 | US$38.59M | US$31.67M | n/a | 1.6× | n/a | 1.6× | −38.5% | 0.4× | n/a |
| HUMASIS Co., Ltd. · KRX:205470 | US$37.49M | −US$89.15M | n/a | −3.8× | n/a | 0.2× | −49.2% | 0.0× | n/a |
| Mabion SA · GPW:MAB | US$35.44M | US$42.01M | n/a | 9.7× | n/a | 6.0× | −321.4% | 1.3× | n/a |
| Trajan Group Holdings Ltd · ASX:TRJ | US$34.94M | US$64.98M | n/a | 0.6× | 7.6× | 0.5× | −0.4% | 0.6× | n/a |
| Novacyt SAS · EURONEXT:ALNOV | US$33.87M | US$35.59M | n/a | 0.8× | n/a | 1.4× | −102.4% | 0.6× | n/a |
| Rapid Micro Biosystems, Inc. · NASDAQ:RPID | US$33.56M | US$46.06M | n/a | 1.3× | n/a | 3.8× | −138.2% | 2.2× | 1.41 |
| Median of the others | US$38.04M | US$42.12M | 38.1× | 0.8× | 18.0× | 1.5× | −25.9% | 0.5× | 1.38 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 26.00 GBX · Analysts' mean
- EPS, year to Sep 2026
- -0.014 · 1 analyst
- Revenue, year to Sep 2026
- 8M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Bram Goorden | Chief Executive Officer |
| Grant Nash | Chief Financial Officer, Chief Operating Officer and Company Secretary |
| James Chandler | Chief Business Officer |
| Tanya Voloshen | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Mark Warne | Non-executive chair |
| Bram Goorden | Chief Executive Officer |
| Dipti Amin | Non-executive Director |
| Grant Nash | Chief Financial Officer, Chief Operating Officer and Company Secretary |
| Kate Rogers | Non-Executive Director and Senior Independent Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| IXICO (LSE:IXI) Q2 2026 Earnings Call | Tue, May 19, 2026 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) Q4 2025 Earnings Call | Tue, Dec 09, 2025 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) — Capital Markets Day | Thu, Oct 30, 2025 · 10:00 AM ET | Replay |
| IXICO (LSE:IXI) — Interim results for the six months ended 31 March 2025 | Tue, May 20, 2025 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) — Full Year Results | Thu, Dec 05, 2024 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) — Investor Presentation | Tue, May 21, 2024 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) — Investor Presentation | Tue, Dec 05, 2023 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) — Investor Presentation | Tue, May 23, 2023 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) — Full Year Results | Wed, Dec 07, 2022 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) — Interim Results | Tue, May 24, 2022 · 11:30 AM ET | Replay |
All 14 calls
| Call | When | Status |
|---|---|---|
| IXICO (LSE:IXI) — Final Results for the year ended 30 September 2021 | Tue, Dec 07, 2021 · 11:30 AM ET | Replay |
| IXICO (LSE:IXI) — Half-year results for the six months ended 31 March 2021 | Tue, May 25, 2021 · 10:30 AM ET | Replay |
| IXICO (LSE:IXI) — Final Results for the year ended 30 September 2020 | Wed, Dec 02, 2020 · 10:30 AM ET | Replay |
| IXICO (LSE:IXI) — Investor Presentation | Tue, Aug 25, 2020 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | May 20, 2025 | +35.6% |
| Q4 2024 | Dec 20, 2024 | −2.1% |
| Quarter to Dec 31, 2023 | Jan 25, 2024 · Before open | −18.0% |
| Q4 2023 | Dec 5, 2023 · After close | −3.5% |
| Quarter to Jun 30, 2023 | Aug 30, 2023 | 0.0% |
| Q2 2023 | May 23, 2023 · Before open | −11.4% |
| Quarter to Dec 31, 2022 | Mar 1, 2023 | 0.0% |
| Q4 2022 | Dec 7, 2022 · Before open | −9.4% |
| Q3 2022 | Aug 31, 2022 | +12.7% |
| Q2 2022 | May 24, 2022 | −9.4% |
All 14 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2022 | Mar 2, 2022 | 0.0% |
| Q4 2021 | Dec 7, 2021 | +23.0% |
| Q3 2021 | Sep 1, 2021 | +0.7% |
| Q2 2021 | May 25, 2021 | +6.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (April 2026) | Investor day | 20 slides | Apr 1, 2026 |
| Ixico Plc Ord New — FY2025 Earnings Presentation | Earnings | 20 slides | Dec 9, 2025 |
| Investor Day (October 2025) | Investor day | 53 slides | Oct 30, 2025 |
| H1 2025 Earnings Presentation | Earnings | 20 slides | May 2025 |
| FY2024 Earnings Presentation | Earnings | 24 slides | December 2024 |
| FY2023 Earnings Presentation | Earnings | 35 slides | Dec 5, 2023 |
| H1 2023 Earnings Presentation | Earnings | 30 slides | May 23, 2023 |
| FY2022 Earnings Presentation | Earnings | 20 slides | Dec 7, 2022 |
| FY2021 Earnings Presentation | Earnings | 19 slides | Dec 7, 2021 |
| FY2020 Earnings Presentation | Earnings | 20 slides | Dec 2, 2020 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2019 Earnings Presentation | Earnings | 30 slides | Dec 4, 2019 |
Financings
| Raise | Date |
|---|---|
| Private placement of new ordinary shares Update: private placement | Apr 16, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M | 9.53M | 7.56M | 5.39M | 4.10M | 3.27M |
| Cost of revenue | 3.63M | 3.06M | 3.40M | 3.87M | 3.66M | 3.62M | 2.62M | 2.22M | 1.79M | 1.68M |
| Gross profit | 2.91M | 2.71M | 3.27M | 4.77M | 5.53M | 5.91M | 4.94M | 3.17M | 2.31M | 1.59M |
| Research and development | 1.33M | 1.50M | 925.0K | 1.22M | 1.24M | 1.31M | 1.00M | 1.03M | 1.26M | 1.58M |
| Selling, general and administrative | 2.49M | 2.91M | 2.34M | 2.58M | 2.44M | 2.82M | 2.74M | 2.45M | 2.31M | 2.16M |
| Operating income | -2.53M | -2.15M | -1.44M | 908.0K | 1.12M | 236.0K | 364.0K | -797.0K | -1.43M | -2.16M |
| Depreciation and amortization | 411.0K | 475.0K | 625.0K | 639.0K | 609.0K | 438.0K | 112.0K | 152.0K | 192.0K | 347.0K |
| EBITDA | -2.12M | -1.68M | -812.0K | 1.55M | 1.73M | 674.0K | 476.0K | -645.0K | -1.24M | -1.82M |
| Interest expense | 16.0K | 25.0K | 29.0K | 33.0K | 22.0K | 18.0K | 25.0K | 0 | 0 | 0 |
| Income before tax | -2.45M | -2.09M | -1.36M | 885.0K | 1.10M | 696.0K | 366.0K | -793.0K | -1.91M | -2.87M |
| Income tax | -798.0K | -93.0K | -183.0K | -147.0K | -415.0K | -256.0K | -66.0K | -125.0K | -375.0K | -750.0K |
| Net income | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M | 952.0K | 432.0K | -668.0K | -1.54M | -2.12M |
| Earnings per share, basic | -0.02 | -0.04 | -0.02 | 0.02 | 0.03 | 0.02 | 0.01 | -0.02 | -0.06 | -0.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M | 7.95M | 7.26M | 7.86M | 2.41M | 3.12M |
| Receivables | 2.70M | 2.21M | 945.0K | 3.00M | 3.29M | 2.76M | 1.93M | 2.11M | 1.25M | 1.01M |
| Inventory | 1 | 1 | 1 | 1 | 1 | 1 | ||||
| Current assets | 6.23M | 4.49M | 6.29M | 9.25M | 10.5M | 10.3M | 10.1M | 10.2M | 4.32M | 5.04M |
| Property, plant and equipment | 817.0K | 1.08M | 1.01M | 316.0K | 77.0K | 60.0K | 88.0K | |||
| Total assets | 13.8M | 11.2M | 13.0M | 14.7M | 14.3M | 12.1M | 10.7M | 10.3M | 4.51M | 5.68M |
| Accounts payable | 75.0K | 83.0K | 86.0K | 254.0K | 734.0K | 176.0K | 597.0K | 339.0K | 270.0K | 216.0K |
| Current liabilities | 2.06M | 1.57M | 1.28M | 1.74M | 2.15M | 2.67M | 2.78M | 3.01M | 1.80M | 1.49M |
| Total debt | 179.0K | 314.0K | 387.0K | 516.0K | 597.0K | 213.0K | ||||
| Total liabilities | 2.10M | 1.72M | 1.56M | 2.16M | 2.78M | 2.98M | 2.78M | 3.01M | 1.82M | 1.60M |
| Shareholders' equity | 11.7M | 9.46M | 11.4M | 12.5M | 11.5M | 9.12M | 7.92M | 7.33M | 2.69M | 4.08M |
| Shares outstanding | 89.5M | 48.3M | 48.3M | 50.8M | 50.4M | 47.5M | 46.8M | 33.8M | 26.9M | 24.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -883.0K | -1.73M | 302.0K | 1.43M | 614.0K | 1.94M | -130.0K | 355.0K | -644.0K | -1.53M |
| Capital spending | -51.0K | -471.0K | -1.96M | -2.25M | -2.15M | -1.14M | -217.0K | -60.0K | -21.0K | -24.0K |
| Free cash flow | -934.0K | -2.20M | -1.66M | -815.0K | -1.54M | 795.0K | -347.0K | 295.0K | -665.0K | -1.56M |
| Cash from investing | -870.0K | -377.0K | -1.86M | -2.25M | -2.15M | -1.14M | -513.0K | -71.0K | -49.0K | 75.0K |
| Cash from financing | 3.50M | -134.0K | -156.0K | -114.0K | 270.0K | -112.0K | 48.0K | 5.16M | 5.16M | 2.71M |
| Share buybacks | 314.0K | 65.0K | 48.0K | 5.50M | 2.71M | |||||
| Change in cash | 1.75M | -2.24M | -1.74M | -915.0K | -1.26M | 681.0K | -597.0K | 5.45M | -706.0K | 1.19M |
Cap table
Built by 6ix from IXICO PLC’s releases
- Common shares
- 218,974,282
- Fully diluted
- 218,974,282
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 218,974,282 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 218,974,282 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bram Goorden | Chief Executive Officer · Since at least Oct 22, 2026 |
| Dipti Amin | Non-executive Director · Since at least Mar 31, 2026 |
| Grant Nash | Chief Financial Officer, Chief Operating Officer and Company Secretary · Since at least Oct 29, 2026 |
| James Chandler | Chief Business Officer · Since at least Apr 16, 2026 |
| Kate Rogers | Non-Executive Director and Senior Independent Director · Since at least Jan 23, 2026 |
| Mark Warne | Non-executive chair · Since at least Mar 31, 2026 |
| Tanya Voloshen | Chief Commercial Officer · Since at least Feb 5, 2026 |
Log in to ask 6ix AI your own questions about IXICO PLC.